-83.9%
RIVN vs GSK
+37.0%
-120.9%
-95.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.7% | -2.7% | +5.4% | +3.1% |
| 7D | +4.1% | -4.2% | +8.3% | +4.6% |
| 30D | +1.1% | -7.5% | +8.6% | +2.0% |
| 3M | -4.0% | -3.3% | -0.7% | -3.6% |
| 6M | +5.2% | -9.3% | +14.5% | +6.3% |
| YTD | -18.0% | +1.6% | -19.6% | -18.2% |
| 1Y | +15.6% | +25.5% | -9.9% | +12.5% |
| 3Y | -30.0% | +49.3% | -79.3% | -34.5% |
| All | -83.9% | +37.0% | -120.9% | -86.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling